Skeletal disorders

Spine Surgery Relieves Pain for St. Joseph's Children's Hospital Patient with Severe Case of the Spinal Disorder Kyphosis

Retrieved on: 
Wednesday, January 6, 2021

"As soon as I saw Justin I knew he was suffering from kyphosis, a spinal disorder in which an excessive curve of the spine causes a bowing or rounding of the upper back," said Dr. Siambanes.

Key Points: 
  • "As soon as I saw Justin I knew he was suffering from kyphosis, a spinal disorder in which an excessive curve of the spine causes a bowing or rounding of the upper back," said Dr. Siambanes.
  • "An X-ray confirmed that he had a severe form of the disorder, known as Scheuermann's kyphosis."
  • According to Dr. Siambanes, normal vertebrae in the thoracic spine are rectangular-shaped and have a soft cushion disc between each one.
  • "Unlike a patient with the milder form of postural kyphosis, those with Scheuermann's kyphosis cannot correct their curve simply by trying to stand up straight."

CrossRoads® Extremity Systems, LLC Announces Launch Of The DynaBunion™ 4D Minimal-Incision Lapidus System For Bunion Corrections

Retrieved on: 
Wednesday, January 6, 2021

MEMPHIS,Tenn., Jan. 6, 2020 /PRNewswire/ -- CrossRoads Extremity Systems is proud to announce the launch of its 4-D minimally-invasive DynaBunion Lapidus System for surgical bunion repair.

Key Points: 
  • MEMPHIS,Tenn., Jan. 6, 2020 /PRNewswire/ -- CrossRoads Extremity Systems is proud to announce the launch of its 4-D minimally-invasive DynaBunion Lapidus System for surgical bunion repair.
  • This system enables surgeons to restore normal foot anatomy by realigning and fusing the bones in four different dimensions through small incisions.
  • CrossRoads also provides the MINIbunion minimally-invasive bunion correction system that can deliver a walking recovery for patients with less severe bunions.
  • EcoSMART reduces the inefficiencies of traditional non-sterile instrument trays and eliminates the waste associated with typical disposable instruments.

Global Osteoarthritis Therapeutics Market (2020 to 2025) - Personalized Medicines for Osteoarthritis Presents Opportunities

Retrieved on: 
Tuesday, January 5, 2021

The global osteoarthritis therapeutics market is projected to reach USD 11 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.

Key Points: 
  • The global osteoarthritis therapeutics market is projected to reach USD 11 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.
  • Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020
    Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics.
  • On the basis of route of administration, the osteoarthritis therapeutics market has been segmented into oral, topical, and parenteral routes.
  • Based on the distribution channel, the osteoarthritis therapeutics market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

Exagen Inc. Partners with Oregon’s St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

Retrieved on: 
Monday, January 4, 2021

St. Charles has a far-reaching impact on the health and wellbeing of the communities they serve.

Key Points: 
  • St. Charles has a far-reaching impact on the health and wellbeing of the communities they serve.
  • Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.
  • Exagens goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune related diseases, including rheumatoid arthritis and lupus.
  • Headquartered in Bend, OR, St. Charles Health System, Inc., owns and operates St. Charles Bend, Madras, Prineville and Redmond.

The Worldwide Osteoarthritis Therapeutics Industry is Expected to Reach $11 Billion by 2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 4, 2021

The global osteoarthritis therapeutics market is projected to reach USD 11 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.

Key Points: 
  • The global osteoarthritis therapeutics market is projected to reach USD 11 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.
  • Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020
    Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics.
  • On the basis of route of administration, the osteoarthritis therapeutics market has been segmented into oral, topical, and parenteral routes.
  • Based on the distribution channel, the osteoarthritis therapeutics market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

Osteoarthritis Therapeutics Market, 2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 30, 2020

The "Osteoarthritis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Osteoarthritis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global osteoarthritis therapeutics market grew at a CAGR of around 8% during 2014-2019.
  • Looking forward, the publisher expects the global osteoarthritis therapeutics market to continue its moderate growth during the next five years.
  • What is the structure of the global osteoarthritis therapeutics market and who are the key players?

Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain

Retrieved on: 
Monday, December 21, 2020

TEL AVIV, Israel, Dec. 21, 2020 /PRNewswire/ -- Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to initiate a global multi-center Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain in knee osteoarthritis (OA).

Key Points: 
  • TEL AVIV, Israel, Dec. 21, 2020 /PRNewswire/ -- Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to initiate a global multi-center Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain in knee osteoarthritis (OA).
  • The focus of current treatment for OA is to reduce pain and improve function of the affected joints.
  • MM-II is a novel non-opioid intra-articular injection that leverages the physical properties of proprietary liposomes and an innovative mechanism-of-action to provide sustainable relief of symptomatic knee OA pain.
  • Moebius Medical ( www.moebiusmedical.com )is a clinical stage biotechnology company that is developing novel treatments for osteoarthritis.

Kyle O. Colle, D.O., FACOS, is recognized by Continental Who's Who

Retrieved on: 
Friday, December 18, 2020

Additionally, Dr. Colle offers cryopreserved amniotic suspension injections for osteoarthritis and painful joints when other therapies have failed or are not enough.

Key Points: 
  • Additionally, Dr. Colle offers cryopreserved amniotic suspension injections for osteoarthritis and painful joints when other therapies have failed or are not enough.
  • Dr. Colle maintains his excellent reputation for his down-to-earth and accessible style that helps patients feel at ease under his care.
  • To prepare for his distinguished career, Dr. Colle graduated from Nova Southeastern University with his Doctorate of Osteopathic Medicine degree in 1996.
  • Dr. Colle dedicates this honorable recognition to Dr. Volker Sonntag, M.D., Dr. Mitchell Levine, M.D., and Dr. Hamid Abbasi.

$62.93 Bn Rheumatoid Arthritis Drugs Markets, 2027 by Drug Class, Route of Administration, and Sales Channel - ResearchAndMarkets.com

Retrieved on: 
Friday, December 18, 2020

The "Rheumatoid Arthritis Drugs Market by Drug Class, Route of Administration, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rheumatoid Arthritis Drugs Market by Drug Class, Route of Administration, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global rheumatoid arthritis drugs market was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.
  • Rheumatoid arthritis is an autoimmune disease that majorly affects joints along with articular tissues and extra-articular organs.
  • The global rheumatoid arthritis drugs market is segmented into drug class, route of administration, sales channel, and region.

Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Retrieved on: 
Thursday, December 17, 2020

We look forward to continuing to work closely with Ultragenyx to make setrusumab available to the OI community worldwide.

Key Points: 
  • We look forward to continuing to work closely with Ultragenyx to make setrusumab available to the OI community worldwide.
  • Most importantly, setrusumab is a promising option for patients with osteogenesis imperfecta, which is one of the most common genetic bone diseases associated with frequent bone fractures.
  • Under the terms of the collaboration, Ultragenyx will lead future global development of setrusumab in both pediatric and adult patients.
  • Mereo granted Ultragenyx an exclusive license to develop and commercialize setrusumab in the US and rest of the world, excluding Europe where Mereo retains commercial rights.